Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SON-DP in Advanced Solid Tumors
NCT05989724Phase 1Recruiting
- Sponsor
- Qurgen
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of SON-DP in solid tumor, breast cancer, pancreatic cancer (PC) and 2 more, sponsored by Qurgen. Primary endpoints: Number of participants with AEs, abnormal vital signs, ECG, labs, physical exams, and ECOG status up to 7 months and Maximum Tolerated Dose / Recommended Phase 2 Dose at 28 days. Started Sep 2023; status: recruiting.
02
Drugs
SON-DP
03
Conditions
solid tumorbreast cancerpancreatic cancer (PC)ovarian cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05989724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05989724.